CD4/CD8 ratio was variable in patients with newly diagnosed multiple myeloma (3.67 ± 1.27) but not significantly different from HDs (1.43 ± 0.1) or patients with early relapsed multiple myeloma (1.18 ± 0.2). Here, CD4 is linked to AL amyloidosis.